Aumake secures $10 million exclusive global distribution deal with EZZ Life Sciences
Aumake (ASX: AUK) has signed a four-year exclusive global distribution agreement with EZZ Life Sciences (ASX: EZZ) targeting minimum sales of $10 million. The Aumake EZZ Life Sciences partnership formalises and expands an existing commercial relationship between the two ASX-listed companies, granting Aumake exclusive rights to distribute high-margin nutraceutical products including EZZ Glutathione Health Support, EZZ Vitality Boost, and EZZ Sleep.
The agreement sets minimum sales targets of $2.5 million per contract year, with scope to expand to co-developed products tailored for the China market. Aumake has recorded more than $2.1 million in nutraceutical sales since 2025, comprising $1.6 million through wholesale B2B channels and $0.5 million via B2C platforms. The deal provides Aumake with contracted minimum revenue targets and exclusive access to established EZZ products, offering greater visibility over near-term sales forecasting.
What are nutraceutical distribution agreements?
Nutraceutical distribution agreements are commercial contracts that grant one company exclusive or non-exclusive rights to sell health supplements, vitamins, and functional food products developed by another company. These arrangements typically involve the distributor leveraging the brand owner’s intellectual property and product formulations without bearing the capital costs of research and development.
The cooperative manufacturing model outlined in this agreement allows Aumake to market and sell EZZ-branded products through its existing sales channels whilst EZZ retains ownership of all intellectual property and branding. This structure enables Aumake to generate recurring revenue from established products without the time and capital required to develop proprietary formulations.
Exclusive global distributor status holds commercial value because it prevents the brand owner from appointing competing distributors in the same territory. For Aumake, this exclusivity protects its market position and investment in building sales channels for EZZ products.
Key terms of the Aumake-EZZ partnership
The agreement establishes a performance-based contractual structure with automatic termination provisions if minimum sales targets are not met. Failure to achieve either the aggregate $10 million requirement or the annual $2.5 million minimum results in automatic termination of worldwide exclusive rights.
EZZ retains full ownership and control of intellectual property and branding, with Aumake responsible for sales and marketing through its B2C e-commerce platforms and B2B distribution network. The nutraceutical segment represents the highest-margin category within Aumake’s Nutritionals products channel.
| Term | Detail |
|---|---|
| Territory | Global |
| Exclusivity | Exclusive across all channels for covered products |
| Minimum commitment | $10 million over 4 years ($2.5 million per year) |
| Termination trigger | Failure to meet annual or aggregate minimums |
| Brand & IP ownership | EZZ retains full control |
The automatic termination clause creates commercial accountability, requiring Aumake to meet defined performance benchmarks to retain exclusive distribution rights. This structure aligns incentives between both parties whilst providing EZZ with recourse if sales targets are not achieved.
Chairman’s perspective on the partnership
Dr Anthony Noble, Chairman of Aumake, positioned the deal as validation of the company’s strengthened commercial processes implemented in 2026. He stated the partnership expansion with EZZ follows enhanced compliance frameworks and tighter business processes that were prerequisites for securing the agreement.
Dr Anthony Noble, Chairman
“Successfully completing and executing this distribution partnership with EZZ and, we hope, far surpassing the minimum value in the contract, will serve as a proof point for other brands to collaborate with us in the Chinese e-commerce and B2B / retail distribution markets.”
Dr Noble referenced the proposed rebrand to Xenitra (ASX: XEN), which is subject to shareholder approval, as reflecting broader ambitions across products, markets and value generation. He stated the company expects to announce additional partnerships “in the coming weeks,” suggesting the EZZ agreement may be the first of multiple distribution deals.
The forward-looking statement positions this partnership as a demonstration case for attracting additional brand collaborations, particularly for companies seeking access to Chinese consumer and retail distribution channels.
How this fits Aumake’s growth strategy
The Aumake EZZ Life Sciences partnership leverages existing sales infrastructure rather than requiring new capital deployment. Aumake has demonstrated commercial traction in nutraceutical distribution, with $2.1 million in sales recorded since 2025 split between B2B wholesale ($1.6 million) and B2C e-commerce ($0.5 million) channels.
The company’s dual-channel approach provides multiple routes to market:
- B2C e-commerce platforms targeting Chinese consumers directly
- B2B distribution network supplying retail partners and wholesale buyers
- High-margin product category within the Nutritionals segment
- Global exclusive rights with strategic focus on China market demand
- Scope for product range expansion through co-development provisions
The agreement includes provisions for developing new products specifically tailored to meet demand in the China market. This co-development clause allows Aumake to influence product formulation and positioning whilst EZZ retains intellectual property ownership.
By securing exclusive global distribution rights for an established product range, Aumake gains predictable revenue targets whilst potentially enhancing return on invested capital through existing channel infrastructure. The $2.5 million annual minimum provides a baseline revenue floor, with upside potential if actual sales exceed contracted minimums.
About EZZ Life Science Holdings
EZZ Life Science Holdings (ASX: EZZ) is a life sciences company focused on consumer health products with operations across Australia, New Zealand, China and international markets. The company employs an omnichannel distribution model combining e-commerce and traditional retail channels.
Partnering with another ASX-listed company provides transparency regarding the counterparty’s financial position, regulatory compliance, and operational capabilities. Both companies are subject to continuous disclosure obligations under ASX Listing Rules.
What to watch next
The agreement establishes clear performance benchmarks that investors can monitor through quarterly reporting cycles. Near-term catalysts include:
- Shareholder approval for the proposed Xenitra rebrand
- Additional partnership announcements flagged for “coming weeks”
- Quarterly sales updates tracking progress against the $2.5 million annual minimum
- Product range expansion under co-development provisions for China market
The minimum sales targets provide quantifiable metrics for assessing execution quality. Aumake must achieve $2.5 million in annual sales to maintain exclusive distribution rights, with failure to meet either annual or aggregate targets triggering automatic termination.
Dr Noble’s reference to “many future collaborations” opening to a “refreshed and rejuvenated company” suggests the Aumake EZZ Life Sciences partnership may serve as a template for additional distribution agreements. Investors should monitor whether similar minimum-commitment structures are replicated in subsequent deals.
The co-development provision for China-specific products represents potential upside beyond the initial product range, though commercial success will depend on product-market fit and competitive positioning in Chinese nutraceutical markets.
Want the Next Consumer Deal in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive alerts the moment market-moving announcements hit the ASX across tech, healthcare, finance, consumer, and manufacturing sectors.